Why the study?
Do beta2-adrenergic receptor polymorphisms (Arg16Gly and Gln27Glu) affect the risk of incident cardiovascular events in the elderly?
Do beta2-adrenergic receptor polymorphisms (Arg16Gly and Gln27Glu) affect the risk of incident cardiovascular events in the elderly?
The Glu27 allele of the beta2-adrenergic receptor is associated with a reduced risk of incident coronary events in an elderly population.
May support Glu27 as protective against coronary events in elderly; leaves open replication and clinical utility of beta2-adrenergic genotyping.
BACKGROUND: Genetic polymorphisms at codons 16 and 27 of the beta2-adrenergic receptor have been associated with altered response to sympathetic stimulation. We examined these polymorphisms in relation to cardiovascular event risk in the Cardiovascular Health Study. METHODS AND RESULTS: A total of 808 black and 4441 white participants (mean age, 73 years) were genotyped for the Arg16Gly and Gln27Glu polymorphisms of the beta2-adrenergic receptor. There were 702 incident coronary events, 438 ischemic strokes, and 1136 combined cardiovascular events during 7 to 10 years of follow-up. Allele frequencies differed by race but not by age or hypertension status. Glu27 carriers had a lower risk of coronary events than Gln27 homozygotes (hazard ratio, 0.82; 95% CI, 0.70 to 0.95), and there was a suggestion of decreased risk among Gly16 carriers compared with Arg16 homozygotes (hazard ratio, 0.88; 95% CI, 0.72 to 1.07). There was no association of beta2-adrenergic receptor genotype with ischemic stroke or combined cardiovascular events. CONCLUSIONS: The Glu27 allele of the beta2-adrenergic receptor was associated with a lower risk of incident coronary events in this elderly population.
No takes yet. Share an insight, caveat, or question.
Heckbert et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: